Twist Bioscience Corporation — News

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price shot up 10.3% during mid-day trading on Wednesday after Piper Sandler raised their price target on the stock from $85.00 to $115.00. Piper Sandler currently has an overweight rating on the stock. Twist Bioscience traded as high as $111.88 and last traded at $109.72. 593,619

defenseworld.net - 2026-08-06 03:14:04

Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.

seekingalpha.com - 2026-08-05 10:08:02

Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten pu

gurufocus.com - 2026-08-05 00:00:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio.

businesswire.com - 2026-08-04 23:45:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.

businesswire.com - 2026-08-04 16:01:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and Res.

businesswire.com - 2026-08-04 08:00:00

First Trust Advisors LP acquired a new position in Twist Bioscience Corporation (NASDAQ: TWST) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 104,650 shares of the company's stock, valued at approximately $4,973,000. First Trust Advisors LP owned

defenseworld.net - 2026-08-04 04:05:30

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

seekingalpha.com - 2026-08-03 14:39:54

Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance.

benzinga.com - 2026-08-03 12:13:44

Twist Bioscience NASDAQ: TWST reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year revenue outlook and said it remains on track to reach adjusted EBITDA breakeven in the fiscal fourth quarter.

marketbeat.com - 2026-08-03 11:03:03

Twist Bioscience (TWST) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.47 per share a year ago.

zacks.com - 2026-08-03 09:26:03

[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights

gurufocus.com - 2026-08-03 08:00:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal third quarter 2026 earnings report and the investor presentation, or click https://investors.twist.

businesswire.com - 2026-08-03 07:15:00

Allspring Global Investments Holdings LLC purchased a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 455,446 shares of the company's stock, valued at approximately $22,563,000. Allspring Global Investments Holdings LLC owned approximately 0.74%

defenseworld.net - 2026-07-21 03:07:56

Thrivent Small Cap Growth Fund returned 25.54% during the quarter, modestly underperforming the Russell 2000 Growth Index return of 25.71%. JFrog reported stronger than expected revenue growth, reinforcing the view that customers are consolidating around JFrog as software delivery and AI-assisted development become more complex. Guidewire underperformed amid a valuation reset in higher-multiple software in addition to not raising its FY26 ARR guide due to timing of a few deals slipping to the subsequent quarter.

seekingalpha.com - 2026-07-19 10:53:00

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

seekingalpha.com - 2026-07-15 13:56:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third quarter ended June 30, 2026, before the opening of the market on August 3, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business.

businesswire.com - 2026-07-15 08:00:00

The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.

forbes.com - 2026-06-17 11:45:12

12,000 shares were exercised from options and sold for a total of ~$673,000 on May 12, 2026. All shares were transacted directly via option exercise and immediate sale; no indirect entities or gifts were involved.

fool.com - 2026-06-12 15:36:45

Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com - 2026-06-12 09:26:07

This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains.

fool.com - 2026-06-06 14:19:08

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

fool.com - 2026-06-05 08:45:31

This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains.

fool.com - 2026-06-04 17:10:09

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

zacks.com - 2026-06-02 13:10:18

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar”.

businesswire.com - 2026-05-27 08:00:00

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

seekingalpha.com - 2026-05-26 11:07:05

DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.

businesswire.com - 2026-05-08 09:08:00

Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.

seekingalpha.com - 2026-05-07 09:45:44